Cardiac devices are systems implanted or used during interventional procedures to modify an electrical, vascular or structural function of the heart. They encompass very different technologies: pacemakers support heart rate and the sequence of cardiac activation; implantable defibrillators detect and treat certain ventricular arrhythmias; stents keep a coronary segment open; and transcatheter valve prostheses or occluders correct specific anatomical abnormalities. Benefit depends on the match between the clinical indication, device characteristics and the body's response; technical success of implantation alone is therefore not sufficient to assess the outcome.
Complications may arise from vascular access, device deployment, interaction with blood and tissues, mechanical or electronic problems, or progression of the underlying heart disease. An injury sustained during a procedure may become apparent immediately, whereas infectious colonization, tissue growth within a stent or wear of a lead may emerge after very long intervals. Moreover, a technically correct treatment can have adverse physiological effects: continuous right ventricular pacing, for example, can impair the coordination of contraction in a susceptible patient even when the generator and lead are functioning normally.
There is no single complication rate applicable to all devices. Results depend on the population, procedural complexity, length of follow-up and event definitions. In the Danish nationwide cohort of 5,918 cardiac electronic device procedures published in 2014, 9.5% of patients experienced at least one complication; this historical figure encompassed different events and does not represent the current probability of any individual complication after every implantation. Comparisons between studies must also distinguish initial implantation from generator replacements, revisions and system upgrades, each of which entails specific exposures and risks.
A coherent clinical approach therefore distinguishes three areas. With pacemakers and defibrillators, interactions among electrical sensing, pacing, leads and tissues predominate; in complications of coronary interventions, preserving epicardial and microvascular flow is the central concern; and in complications of structural interventions, device position, stability, sealing and haemodynamic performance are particularly important. Shared mechanisms help identify the problem, but diagnostic confirmation and treatment remain specific to each complication.
Every implantation must be based on a documented therapeutic need. Permanent pacing may correct clinically significant bradycardia or a high-risk conduction block, whereas an implantable defibrillator reduces the risk of arrhythmic death in selected populations. Percutaneous revascularization restores the lumen of a diseased coronary artery; transcatheter valve replacement relieves the obstruction caused by a stenotic valve; and closure of an atrial septal defect eliminates a shunt when indicated. This rationale differs from closure of a patent foramen ovale, which in selected patients is primarily intended to prevent recurrent paradoxical embolism after appropriate assessment of other causes of stroke. Confusing these objectives leads to overestimation of the benefits of implantation and underestimation of its risks.
Direct causes of injury include mechanical damage to a vessel or cardiac wall, thrombotic obstruction, microbial contamination of implanted material and interruption of an electrical circuit. These events are distinct from the factors that increase their likelihood. Renal impairment, diabetes, frailty, low body weight, antithrombotic treatment, previous procedures and greater anatomical complexity modify risk but do not necessarily cause a complication. The role of each factor also varies with the event: calcification may prevent adequate stent expansion or sealing of a valve prosthesis, whereas the number of leads and previous revisions mainly influence access difficulties, venous obstruction and infection risk.
Vascular access introduces the first area of vulnerability. Venous puncture for a transvenous system can injure adjacent structures, causing pneumothorax, bleeding or arterial injury; arterial access for catheter-based interventions can be complicated by haematoma, pseudoaneurysm, dissection, occlusion or retroperitoneal haemorrhage. Introducer diameter, vessel depth, tortuosity and calcification influence the balance between trauma and the ability to achieve haemostasis. Ultrasound guidance and appropriate access-site selection reduce particular risks without making procedures requiring different equipment and haemodynamic conditions equivalent.
Once implanted, the material interacts with a biologically active environment. Blood-contacting surfaces adsorb plasma proteins and may promote platelet adhesion and fibrin formation; endothelial damage exposes thrombogenic components of the vessel wall. The outcome depends on device surface properties, degree of trauma, flow velocity and the patient's haemostatic status. In coronary stents, underexpansion, residual dissections and incomplete endothelial healing may promote thrombosis; along venous leads, contact with the endothelium, local stasis and subsequent fibrotic remodelling are important. Differences between arterial and venous circulation explain why antiplatelet and anticoagulant treatments are not interchangeable.
Tissue repair is essential for implant stabilization but can produce unfavourable effects. In the coronary wall, activation and migration of smooth muscle cells, proliferation and matrix deposition form a neointima; excessive growth narrows the lumen. Drug-eluting stents limit this response through a local antiproliferative effect, without eliminating all mechanisms of failure. Over time, neoatherosclerosis may develop within in-stent tissue, with lipid accumulation and potential destabilization. In-stent restenosis is therefore not merely a recurrence of the original plaque and may require different treatments according to the underlying substrate.
Fibrosis around a lead strengthens its attachment to tissues but may also involve venous walls and cardiac structures. Adhesions and calcification progressively complicate any subsequent extraction; venous narrowing may remain compensated by collateral circulation or become symptomatic. At the tricuspid valve, a lead may interfere with leaflet movement, adhere to a leaflet or involve the subvalvular apparatus. The resulting regurgitation must be distinguished from functional tricuspid regurgitation due to right ventricular or annular dilatation: the presence of a lead alone does not establish causality.
Interaction between microorganisms and an implant is another shared mechanism. Bacteria introduced during the procedure or reaching the device through the bloodstream may adhere to host-protein-coated surfaces and organize into a biofilm. The extracellular matrix and metabolic characteristics of bacterial populations promote persistence, reducing the effectiveness of antibiotics alone. In electronic systems, pocket infection may extend along the leads; alternatively, bacteraemia may directly involve the intravascular components. In valve prostheses, infection may damage not only the device but also surrounding tissues, causing abscesses, dehiscence and valve regurgitation.
Other complications are related to the activation sequence. Myocardium paced from a non-physiological ventricular site may be activated slowly through muscle tissue, with regional delays that impair contraction, filling and regional wall work. Uncoordinated atrioventricular pacing may cause the atria to contract while the atrioventricular valves are closed, increasing venous pressures and reducing the atrial contribution to filling. These situations differ from device failure: treatment is delivered, but its temporal or spatial organization is unsuitable for the patient.
Finally, in structural interventions, a device changes cardiac geometry and pressure distribution. An aortic prosthesis that does not seal perfectly against the annulus may allow regurgitant flow outside the valve; expansion near the conduction system may cause atrioventricular block. An occluder requires suitable anatomical rims and correct sizing to remain stable without exerting excessive pressure on tissues. The distinction between the intended result, a tolerable residual abnormality and a clinically significant complication therefore depends on imaging and functional consequences, not simply on the presence of foreign material.
The history must first establish the identity of the system, the indication for implantation and which procedures have subsequently been performed. The procedure date, implant site, number of components, previous infections, revisions and baseline reports are essential clinical information. The temporal relationship between implantation and symptoms guides the differential diagnosis without excluding late events: pleuritic pain immediately after implantation suggests different problems from a loss of electrical effectiveness years later, but perforation or infection may also occur beyond the initial period.
Syncope requires a description of the loss of consciousness, prodromal symptoms, body position, exertion, duration and recovery. In pacemaker recipients, it may indicate inappropriate inhibition, loss of capture or an arrhythmia not prevented by the system; however, it may also result from orthostatic hypotension, vasodepressor reflexes or extracardiac causes. In defibrillator recipients, it is important to determine whether syncope preceded a shock, whether multiple therapies were perceived and whether recovery was complete. Device memory may help reconstruct the event but does not replace assessment of perfusion and neurological status.
Chest pain should be characterized by location, duration, nature, radiation and relationship to breathing, position and exertion. After a coronary procedure, persistent or recurrent pain with instability requires consideration of ischaemia, thrombosis, dissection or perforation. Pleuritic pain after lead implantation may accompany pericardial or pleural injury. Pain localized to the device pocket, especially if increasing and accompanied by swelling or skin changes, suggests haematoma, inflammation or infection. An apparently local explanation must not distract from a concurrent cardiopulmonary problem.
Dyspnoea may develop abruptly because of tamponade, pneumothorax, pulmonary embolism, pulmonary oedema or acute valve regurgitation. Gradual deterioration may reflect pacing-induced dyssynchrony, loss of resynchronization, tricuspid regurgitation, prosthetic dysfunction or progression of heart disease. Orthopnoea, oedema, weight gain and reduced exercise capacity help characterize the congestion phenotype. After TAVI, comparison with the benefit initially achieved is useful: renewed exercise intolerance after an initial improvement warrants reassessment of the prosthesis and other causes of heart failure.
Assessment for infection should include fever, chills, sweating, malaise, weight loss and recent infectious foci. Absence of fever does not exclude pocket infection or endocarditis, especially in older or immunosuppressed patients or after antibiotics. If system components lie in the right heart, cough, pleuritic pain or seemingly respiratory episodes caused by septic emboli may predominate. The appearance of discharge, erosion or generator exposure is a particularly significant local finding and must not be mistaken for normal wound healing.
Current medication must be documented accurately, including actual adherence, interruptions, new medicines and planned procedures. After stenting, discontinuation of antiplatelet agents may contribute to thrombotic risk; anticoagulants and combinations of antithrombotic drugs may promote bleeding. Heart-rate-lowering or antiarrhythmic drugs may affect conduction, arrhythmia frequency and pacing threshold; renal impairment and electrolyte disturbances may amplify these effects. It is also useful to ask whether symptoms occur during electromagnetic exposure, particular arm movements or physical exercise.
Physical examination begins by assessing haemodynamic stability: mental status, blood pressure, heart rate, oxygen saturation, peripheral perfusion and signs of respiratory distress determine urgency. This is followed by cardiac and pulmonary auscultation, venous pressure assessment and examination for congestion. A new murmur may suggest regurgitation; jugular venous distension and hypotension warrant assessment for tamponade or right-sided failure; asymmetric breath sounds after thoracic access raise suspicion of pneumothorax. Absence of the classic tamponade triad does not rule out the condition.
Inspection of the pocket and access sites completes the examination. Swelling, bruising, warmth, erythema, skin tension, discharge and wound integrity are assessed without traumatic manipulation. Diminished peripheral pulses, a bruit at the access site or a pulsatile mass suggest a vascular problem; unilateral arm oedema and superficial venous collaterals suggest impaired venous drainage. A focused neurological examination is required in the presence of focal deficits, speech abnormalities or visual disturbances. All findings must be interpreted in relation to the patient's previous condition and the procedure actually performed.
The first diagnostic priority is to identify conditions in which delay worsens the prognosis. In the presence of shock, hypoxaemia, persistent pain, sustained arrhythmia or an acute neurological deficit, stabilization and investigations proceed simultaneously. A 12-lead ECG documents rhythm, conduction, pacing and possible ischaemic changes; continuous monitoring detects intermittent events. A paced ECG may make repolarization more difficult to interpret, but does not preclude diagnosing acute ischaemia by integrating symptoms, ECG evolution, echocardiography and biomarkers.
For electronic devices, device interrogation is the investigation that links clinical findings to system behaviour. It should assess battery status, pacing mode, pacing percentages, capture thresholds, sensed signal amplitudes, impedances, alerts and stored intracardiac recordings. Comparison with previous checks is often more informative than an isolated value. An increased threshold may result from displacement, fibrosis, perforation or metabolic abnormalities; an impedance change points towards a circuit problem, but apparently normal values do not exclude intermittent defects. Likewise, an episode automatically classified as tachycardia requires review of electrograms before it can be regarded as a true arrhythmia.
Transthoracic echocardiography assesses pericardial effusion, ventricular function, native and prosthetic valves, regurgitation, gradients and possible consequences of residual shunts. After a structural implant, the initial report provides an essential reference: a gradient that has been high from the outset does not necessarily mean the same thing as a recent increase. Transoesophageal echocardiography provides better visualization of many prosthetic structures, septa and vegetations, while three-dimensional imaging may clarify relationships between a lead and the tricuspid valve or the location of a leak.
Chest radiography is useful when pneumothorax, major changes in lead course or changes in generator position are suspected. Computed tomography addresses specific anatomical questions, such as the position of a lead relative to the wall, central venous patency, prosthesis position, or thickening and mobility of valve leaflets. Not all radiological findings are equally relevant: subclinical leaflet abnormalities are not automatically equivalent to clinically significant prosthetic thrombosis and must be correlated with haemodynamic function and symptoms.
Blood tests are selected according to the suspected diagnosis. Full blood count, renal function and electrolytes may document anaemia, bleeding, infection or conditions interfering with electrical function. Troponin must be interpreted in relation to the interval since the procedure and changes over time, because procedure-related myocardial injury is not automatically a new infarction. If haemolysis is suspected after a structural procedure, lactate dehydrogenase, haptoglobin, bilirubin, reticulocytes and a peripheral blood smear help characterize the process and distinguish it from other causes of anaemia.
When endovascular infection is suspected, blood cultures are obtained, preferably before antibiotics if clinical circumstances permit this without dangerous delay. Microorganism identification, persistent bacteraemia, imaging and local signs must be considered together. International definitions of electronic device infection and endocarditis distinguish clinical, microbiological and imaging evidence; a mass on a lead may also represent thrombus or fibrinous material rather than infection. In selected cases, fluorodeoxyglucose PET/CT or labelled white-blood-cell imaging contributes to assessment, taking into account postoperative inflammation and sensitivity limitations.
In coronary intervention failure, angiography documents patency, occlusions, dissections and extravasation. Intracoronary imaging with IVUS or OCT can establish stent expansion, apposition, in-stent tissue, calcification and edge injury. This distinction has immediate implications: narrowing caused by tissue growth should not be managed in the same way as persistent mechanical underexpansion. Reduced flow also requires differentiation of epicardial obstruction from the no-reflow phenomenon, in which microvascular impairment persists despite reopening the main vessel.
There are no universal diagnostic criteria covering all complications of cardiac devices. Diagnosis must identify the event and, where possible, demonstrate the mechanism linking it to the procedure or implant. Academic Research Consortium criteria for stent thrombosis and VARC definitions of valve outcomes have specific purposes and scopes; they cannot be applied indiscriminately to pacemaker malfunction, venous stenosis or haematoma. Research definitions must also be distinguished from the urgent decisions required for an individual patient.
Once a complication has been identified, its extent, reversibility and impact must be established. An isolated electrical abnormality calls for assessment of pacing dependence; vascular injury must be evaluated in terms of bleeding and perfusion; and regurgitation must be quantified alongside ventricular response. The common principle is to distinguish what the device shows from what the patient experiences. A high pacing percentage does not prove cardiomyopathy, a defibrillator alert does not prove a fracture, and an elevated prosthetic gradient alone does not identify the mechanism of dysfunction.
The relationship with the underlying heart disease is crucial. Dyspnoea may be due to progression of heart failure, ischaemia, anaemia, lung disease or renal failure even when an implant is intact. Conversely, an apparently functioning system may contribute to deterioration through dyssynchrony, an inadequate rate, loss of biventricular pacing or induced regurgitation. Assessment therefore integrates ECG, echocardiography, device data and the clinical course, using functional tests or advanced imaging when a specific question remains unresolved.
In electronic systems, remote monitoring enables early detection of parameter changes, arrhythmias and technical alerts. Its usefulness depends on connectivity, alert programming and the availability of a service to receive and interpret transmissions. It does not guarantee continuous emergency surveillance and does not replace immediate assessment of syncope, repeated shocks or severe dyspnoea. Transmissions must also be interpreted in their clinical context, as some variations reflect algorithms, transient conditions or artefacts rather than structural damage.
For a valve prosthesis, a baseline examination and subsequent checks are essential for detecting changes in gradients, regurgitation and ventricular function. Follow-up intervals are tailored to the device, clinical condition and applicable recommendations. After closure of an atrial septal communication, surveillance assesses occluder position, residual shunt, cardiac chamber response and arrhythmias. After PCI, however, indiscriminate repeat coronary angiography in an asymptomatic patient is not equivalent to electronic pacemaker follow-up: testing is selected according to symptoms and risk.
The feasibility of magnetic resonance imaging in patients with electronic devices must be assessed for the entire system. The generator, leads, any abandoned components and manufacturer-specified conditions determine the pathway. In experienced centres, many systems not labelled MR-conditional can also be scanned under dedicated protocols; this is not, however, blanket permission to proceed without checks. Pre-scan programming, monitoring, availability of trained personnel and post-scan assessment are all part of the procedure.
Surveillance also includes a strategy for future interventions. Each additional pocket access or component changes cumulative risk. Before replacement, the indication, clinical status, need for additional functions and opportunities to reduce unnecessary hardware should be reassessed. Decisions to extract or retain non-functioning leads require balancing immediate risk, implant age, venous anatomy, life expectancy and future therapeutic needs. Managing the entire care pathway is part of treatment, not simply a technical maintenance issue.
Treatment is guided by the underlying mechanism and clinical severity. Tamponade, uncontrolled haemorrhage, acute coronary occlusion and unstable arrhythmias require immediate supportive and corrective measures. An electrical complication may be managed temporarily by reprogramming or alternative pacing, but such bridging measures do not necessarily eliminate the defect. Vascular injury may require compression, endovascular therapy or surgery; the choice depends on its location, extent and haemodynamic consequences.
Reprogramming can correct an inappropriate rate, unfavourable atrioventricular interaction, certain tracking phenomena and some inappropriate defibrillator therapies. It must follow an understanding of the event and be followed by confirmation of its effect, avoiding changes that solve one problem while creating another. Structural defects, such as a fracture or clinically significant displacement, may require revision, an additional lead or a different system configuration. Complications of implantable cardiac devices therefore require joint assessment of electrical performance and anatomical integrity.
Confirmed system infection is generally not resolved by antibiotics and simple pocket cleansing. When indicated, complete removal of infected material is combined with targeted antimicrobial therapy and reassessment of the need for reimplantation. The strategy differs when a valve prosthesis is infected, in which case haemodynamic dysfunction, perivalvular extension, the microorganism and surgical risk all matter. In both situations, multidisciplinary discussion helps determine timing and approach without delaying source control when risk is high.
In coronary stent thrombosis, urgent restoration of flow is accompanied by identification of mechanical and pharmacological causes. For restenosis, imaging guides correction of underexpansion, antiproliferative treatment and other techniques appropriate to the substrate. Treatment of valve dysfunction instead requires distinguishing thrombosis, degeneration, mismatch and paravalvular regurgitation: anticoagulation, transcatheter correction and surgery have different indications. Mere suspicion of a prosthetic complication therefore does not justify the same treatment for every patient.
Prevention begins before implantation, with patient selection, anatomical assessment, management of comorbidities and planning antithrombotic treatment. In electronic devices, antibiotic prophylaxis before incision, sterile technique, haemostasis and avoidance of unnecessary pocket re-openings are particularly important. In anticoagulated patients, the perioperative strategy depends on the drug and thromboembolic risk: heparin bridging must not automatically be considered safer. In coronary and structural procedures, correct sizing, imaging and attention to the final result reduce complications directly related to implantation.
Innovation changes risk profiles. Systems without transvenous leads can avoid some pocket or venous complications but introduce different issues involving access, fixation, perforation and long-term management. Conduction system pacing aims to preserve a more physiological activation sequence, with its own technical and follow-up requirements. New prostheses and stents improve deployment and performance, but no technology removes the need for an appropriate indication and clinical follow-up. Choice should be based on demonstrated benefit for the patient's profile and the maturity of the evidence.
Prognosis depends primarily on the nature of the event and the time to correction. A reversible programming problem may resolve without sequelae; endovascular infection, tamponade or coronary occlusion may be life-threatening. Advanced heart failure, kidney disease, frailty and systemic infection further modify risk. Success should be measured not only by disappearance of the technical abnormality but also by functional recovery, absence of recurrence, quality of life and continued efficacy of the original treatment.
Bleeding complications include pocket haematoma and vascular access-site bleeding. The harm extends beyond blood loss: a collection under tension can compromise wound edges, increase pain and length of stay, and promote infection. Any interruption of antithrombotic treatment may in turn expose the patient to thromboembolic events. The balance between bleeding and thrombosis must therefore be reassessed throughout recovery, avoiding automatic decisions based solely on the presence of bruising.
Perforation injury may affect a cardiac chamber or vessel. Lead perforation may cause pericardial effusion, pain and electrical abnormalities; coronary perforation may lead to extravasation and tamponade. Severity depends on the rate of blood accumulation, location and ability to contain the bleeding, not solely on the final effusion volume. Circulatory collapse may be delayed after the procedure and calls for surveillance proportionate to clinical suspicion.
Thrombotic complications take various forms: coronary thrombosis, venous thrombosis around leads, thrombosis involving prostheses or occluders, and embolism. Venous stenosis may remain silent while collateral vessels compensate, but can become critical when further access is needed or the obstruction affects the superior vena cava. A thrombus in the right heart generally embolizes to the pulmonary circulation; the risk of systemic embolism depends on its location and on communications permitting right-to-left passage. Risk assessment must reflect this anatomy.
Infectious consequences range from local inflammation to endocarditis and sepsis. Pocket infection may be the visible sign of more extensive involvement, whereas bacteraemia can present without skin abnormalities. Vegetations, septic emboli, valve lesions and metastatic infectious foci account for systemic severity. Persistence of colonized material may sustain the disease even after apparent improvement with antibiotics.
Electrical complications include loss or inhibition of pacing, failure to detect arrhythmias and inappropriate defibrillator interventions. They may result from programming, component deterioration, interfering signals or changes in the patient's characteristics. Depending on device dependence and the type of abnormality, consequences range from palpitations and reduced exercise capacity to syncope and cardiac arrest. Repeated shocks also have a psychological impact that may persist after technical correction and warrants clinical attention.
Late structural outcomes include pacing-associated cardiomyopathy, lead-related tricuspid regurgitation, prosthetic deterioration and residual shunts. Post-TAVI paravalvular leak may cause volume overload and, in some cases, haemolysis; an obstructed prosthesis instead increases pressure load. After atrial septal closure, device embolization, erosion and occluder thrombosis are distinct from a small residual shunt. Their importance depends on the relationship between the anatomical finding, physiological consequence and potential progression.
Finally, each treatment of a complication may create new risks. Revisions and extractions may cause vascular or cardiac injury; repeated coronary interventions increase the complexity of the treated segment; and procedures on pre-existing prostheses require renewed anatomical planning. Optimal management therefore integrates correction of the current event with preservation of future treatment options. A durable outcome is a system suited to the patient's needs, supported by surveillance capable of detecting changes before they cause irreversible damage.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.